3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 63, n° 3
pages 389-399 (septembre 2010)
Doi : 10.1016/j.jaad.2009.10.038
accepted : 24 October 2009
Original Articles

Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience

Anne A. Lemy, MD a, Véronique del Marmol, MD, PhD b, Athanassios Kolivras, MD b, Whitney A. High, MD, MEng d, Celso Matos, MD c, Marianne Laporte, MD b, Joëlle L. Nortier, MD, PhD a,
a Department of Nephrology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium 
b Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium 
c Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium 
d Dermatology Department, University of Colorado, Aurora, Colorado 

Correspondence to: Joëlle Nortier, MD, PhD, Erasme Hospital, Universite Libre de Bruxelles, Route de Lennik, 808 1070 Brussels, Belgium.

Nephrogenic systemic fibrosis (NSF) is a fibrotic disorder occurring in patients with renal dysfunction. Exposure to gadolinium (Gd)-based contrast agents (GBCAs) during renal impairment is associated with development of NSF.


A cross-referenced search of kidney transplantation and radiology databases at a single institution revealed the prevalence of NSF in the transplant population. Clinical records and skin biopsy specimens from 6 patients with kidney transplant given a diagnosis of NSF were reviewed to identify contributing factors.


Between January 1999 and December 2006, NSF was diagnosed in 6 of 705 patients with kidney transplant (0.9%). Renal function was impaired in all patients. Of 33 patients with kidney transplant exposed to GBCAs, 5 (15.2%) developed NSF. Disease onset ranged from 7 days to 11 months after exposure to GBCAs. All 5 patients exposed to GBCAs who developed NSF were also treated with a β-blocker and clinical improvement was observed with discontinuation. The sixth case NSF appeared unrelated to Gd, without a known exposure, and testing of tissue via mass spectrometry revealed no Gd. Symptoms of NSF in this patient disappeared after administration of darbepoetin was switched from subcutaneous to intravenous injection. One patient with NSF who manifested the highest Gd level in tissue died 22 months after disease onset.


The study represents the retrospective experience of only a single center.


NSF can develop in kidney transplant recipients with altered graft function. In these patients, exposure to GBCAs appears associated with development of NSF. The role of β-blockers in the course of the disease merits further investigation.

The full text of this article is available in PDF format.

Key words : β-blockers, chronic kidney disease, collagenous colitis, erythropoiesis-stimulating agents, erythropoietin, fibrosis, gadolinium, mass spectrometry, nephrogenic fibrosing dermopathy, nephrogenic systemic fibrosis, renal transplantation, ulceration

Abbreviations used : ESA, GBCA, Gd, NSF, sc

 Dr High’s work in this general area is supported by a Career Development Award in Medical Dermatology from the Dermatology Foundation.
 Conflicts of interest: None declared.
 Reprints not available from the authors.

© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline